Spark Therapeutics (NASDAQ:ONCE) has been given a $71.00 price target by analysts at Sanford C. Bernstein in a report released on Wednesday. The firm currently has a “buy” rating on the biotechnology company’s stock. Sanford C. Bernstein’s price objective suggests a potential upside of 58.62% from the stock’s previous close.

A number of other brokerages have also weighed in on ONCE. Goldman Sachs Group reiterated a “buy” rating and issued a $111.00 price target on shares of Spark Therapeutics in a report on Friday, October 6th. BMO Capital Markets set a $89.00 price target on shares of Spark Therapeutics and gave the company a “buy” rating in a report on Tuesday, October 10th. Cowen reiterated a “buy” rating and issued a $95.00 price target on shares of Spark Therapeutics in a report on Tuesday, October 10th. Chardan Capital reiterated a “buy” rating and issued a $100.00 price target on shares of Spark Therapeutics in a report on Friday, October 13th. Finally, Raymond James Financial assumed coverage on shares of Spark Therapeutics in a report on Thursday, October 12th. They issued an “outperform” rating and a $96.00 price target on the stock. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and sixteen have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $80.86.

Shares of Spark Therapeutics (NASDAQ ONCE) traded down $2.96 on Wednesday, hitting $44.76. 4,202,500 shares of the company’s stock were exchanged, compared to its average volume of 475,176. Spark Therapeutics has a 52 week low of $41.06 and a 52 week high of $91.75.

Spark Therapeutics (NASDAQ:ONCE) last announced its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($1.90) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.79) by ($0.11). The company had revenue of $1.90 million during the quarter, compared to analyst estimates of $1.40 million. Spark Therapeutics had a negative net margin of 1,090.11% and a negative return on equity of 60.01%. The firm’s revenue for the quarter was up 45.8% compared to the same quarter last year. During the same quarter last year, the business earned ($1.07) EPS. equities research analysts expect that Spark Therapeutics will post -7.6 earnings per share for the current year.

In other Spark Therapeutics news, insider Katherine A. High sold 5,000 shares of the business’s stock in a transaction on Tuesday, September 26th. The shares were sold at an average price of $86.16, for a total value of $430,800.00. Following the transaction, the insider now owns 215,000 shares in the company, valued at approximately $18,524,400. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Daniel Faga sold 1,500 shares of the business’s stock in a transaction on Tuesday, September 19th. The stock was sold at an average price of $85.00, for a total transaction of $127,500.00. Following the completion of the transaction, the insider now owns 1,500 shares in the company, valued at approximately $127,500. The disclosure for this sale can be found here. Insiders have sold a total of 1,068,809 shares of company stock worth $89,809,385 in the last 90 days. Company insiders own 7.30% of the company’s stock.

Hedge funds have recently modified their holdings of the business. JPMorgan Chase & Co. lifted its holdings in Spark Therapeutics by 15.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,848,988 shares of the biotechnology company’s stock worth $164,986,000 after buying an additional 241,016 shares in the last quarter. BlackRock Inc. lifted its holdings in Spark Therapeutics by 11.6% in the 2nd quarter. BlackRock Inc. now owns 2,053,734 shares of the biotechnology company’s stock worth $122,689,000 after buying an additional 213,520 shares in the last quarter. Amundi Pioneer Asset Management Inc. acquired a new position in Spark Therapeutics in the 3rd quarter worth $5,286,000. TIAA CREF Investment Management LLC lifted its holdings in Spark Therapeutics by 20.3% in the 2nd quarter. TIAA CREF Investment Management LLC now owns 62,480 shares of the biotechnology company’s stock worth $3,733,000 after buying an additional 10,544 shares in the last quarter. Finally, Balyasny Asset Management LLC lifted its holdings in Spark Therapeutics by 104.8% in the 2nd quarter. Balyasny Asset Management LLC now owns 59,400 shares of the biotechnology company’s stock worth $3,549,000 after buying an additional 30,400 shares in the last quarter. Hedge funds and other institutional investors own 94.94% of the company’s stock.

WARNING: This piece was posted by American Banking News and is the property of of American Banking News. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/12/13/spark-therapeutics-once-outperform-rating-reiterated-at-sanford-c-bernstein.html.

About Spark Therapeutics

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Analyst Recommendations for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.